XTL Biopharmaceuticals Sponsored ADR (HHB0) Financial Statements
XTL Biopharmaceuticals Sponsored ADR Financial Overview
XTL Biopharmaceuticals Sponsored ADR's market cap is currently $6.74M. The company's EPS TTM is $-2.88; its P/E ratio is -0.56; XTL Biopharmaceuticals Sponsored ADR is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 451.00K | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 3.00K | $ 0.00 | $ -1.00K | $ -1.00K |
| Operating Income | $ -1.69M | $ -2.17M | $ -765.00K | $ -880.00K | $ -1.03M |
| EBITDA | $ -752.00K | $ -930.00K | $ -764.00K | $ -879.00K | $ -1.03M |
| Net Income | $ -6.97M | $ -1.03M | $ -1.78K | $ -1.35M | $ 435.00K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 144.00K | $ 1.14M | $ 2.01M | $ 3.72M | $ 6.13M |
| Total Assets | $ 166.00K | $ 8.55M | $ 2.43M | $ 4.19M | $ 6.62M |
| Total Debt | $ 269.00K | $ 138.00K | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ 193.00K | $ -233.00K | $ -1.40M | $ -2.09M | $ -2.97M |
| Total Liabilities | $ 420.00K | $ 3.12M | $ 206.00K | $ 187.00K | $ 1.28M |
| Stockholders' Equity | $ -254.00K | $ 5.43M | $ 2.22M | $ 4.00M | $ 5.33M |
| Cash Flow | |||||
| Free Cash Flow | $ -1.02M | $ -1.67M | $ -707.00K | $ -901.00K | $ -1.05M |
| Operating Cash Flow | $ -1.02M | $ -1.62M | $ -707.00K | $ -901.00K | $ -1.05M |
| Investing Cash Flow | $ 522.00K | $ -844.00K | $ 41.00K | $ 36.00K | $ 8.00K |
| Financing Cash Flow | $ 208.00K | $ 1.45M | $ 0.00 | $ 0.00 | $ 385.00K |
Currency in USD